Jinender Kumar
University of Toledo
6 Papers
2 Citations
Jinender Kumar is an academic researcher from University of Toledo. The author has contributed to research in topics: Medicine & Excellence. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Improving the economic and humanistic outcomes for diabetic patients: making a case for employer-sponsored medication therapy management
TL;DR: Pharmacist interventions provided through the employer-sponsored MTM program led to substantial cost savings to the employer with improved patient satisfaction and adherence on the part of employees at the conclusion of the program.
13
POSB17 Ozanimod for the Treatment of Biologic-Experienced Patients with Moderate-to-Severe Ulcerative Colitis: Results from a Systematic Literature Review and Network Meta-Analyses
Kiefer Eaton,Corinne Duperrouzel,P. Bhandari,Samantha Craigie,Ashley Bonner,C. Cameron,Thomas Tencer,Jinender Kumar +7 more
TL;DR: In this paper , the relative efficacy of the oral selective sphingosine-1-phosphate receptor modulator ozanimod (OZA) versus other approved moderate-to-severe ulcerative colitis (UC) therapies in biologic-experienced patients via network meta-analyses (NMA) was compared.
1
A Retrospective Analysis to Identify Factors that Predict Adherence with HMG-CoA Reductase Inhibitors (statins) among University of Toledo Employees with Diabetes
Jinender Kumar
- 01 Jan 2010
TL;DR: In this article, the authors present a table of acknowledgements and acknowledgements for the authors' work: http://www.thespaces.org/ acknowledgements.html
1
MT30 Medtech Innovations in Oncology: A Review of NICE Medtech Innovation Briefings from 2014 to 2022
TL;DR: In this article , the authors evaluate trends in Medtech Innovation Briefings (MIBs) in oncology since its inception in 2014, and they identify trends in MIBs in cancer patients.
MT41 Medical Technology Guidance: A Review to Identify the Evidence Gaps and Data Needs
TL;DR: In this paper , the authors evaluated the trends and data gaps raised by External Assessment Centre (EAC), limiting the acceptance of medical technologies in the National Health Service (NHS).